<DOC>
	<DOCNO>NCT02186860</DOCNO>
	<brief_summary>Traditional standard treatment B cell acute lymphoblastic leukemia perfect fight cancer . Many people respond standard treatment ALL . One possible treatment chimeric antigen receptor ( CAR ) modify T cell infusion . Third generation CAR-T contain Cluster Differentiation 28 ( CD28 ) Cluster Differentiation 137 ( CD137 ) strong effect anti-tumor capacity compare second generation CAR-T . The investigator believe cell CD28 CD137 good chance kill lymphoma cell . In lab , investigator construct third generation CAR contain CD28 CD137 . The investigator start Phase I study aim chemotherapy resistant refractory acute lymphoblastic leukemia patient . The purpose study assess safety effectiveness third generation CAR-T cell patient .</brief_summary>
	<brief_title>Chimeric Antigen Receptor ( CAR ) -Modified T Cell Therapy Treating Patients With Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>Third generation CAR-T strong effect anti-tumor capacity . While people able control clinical complication , conduct third generation CAR-T clinical trial strong demand value . The investigator construct third generation CAR contain CD28 CD137 .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<criteria>Age : 1865 year Patients Cluster Differentiation 19 ( CD19 ) positive B cell malignancy confirm flow cytometry Refractory relapse B cellacute lymphoblastic leukemia No available curative treatment option ( hematopoietic stem cell transplantation ) Stage IIIIV disease Creatinine &lt; 2.5 mg/dl Aspartate transaminasealanine transaminase ratio &lt; 3x normal Bilirubin &lt; 2.0 mg/dl Karnofsky performance status &gt; = 60 Expected survival time &gt; 3 month Adequate venous access apheresis Ability understand provide inform consent Pregnant lactate woman Patients require T cell immunosuppressive therapy Active central nervous system leukemia Any concurrent active malignancy Patients history seizure disorder cardiac disorder Previous treatment immunotherapy product Patients human immunodeficiency virus , hepatitis B C infection Uncontrolled active infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>